Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Combo B-Cell Depletion Advances in SLE

Publish date:: April 29, 2019

Key clinical point: Combination B-cell immunomodulatory therapy with rituximab and belimumab shows considerable promise for treatment of SLE, including lupus nephritis.

Major finding: Eight of 12 patients with active lupus nephritis experienced a long-term renal response to the rituximab/belimumab combo.

Study details: SYNBIoSe-1 was a phase 2a, open-label, single-arm, 104-week, proof-of-concept study of 15 patients with severe SLE.

Disclosures: The presenter reported having no financial conflicts regarding the SYNBIoSe-1 study, which was funded by research grants from the Dutch Kidney Foundation and the Netherlands Organization for Health Research and Development.

Citation:

Reproting from LUPUS 2019

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Nephrology

Dapagliflozin’s CKD performance sends heart failure messages,

DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use,

Survival after kidney transplantation lags in diabetes patients,

Late-onset neutropenia more common than expected in patients on rituximab,

DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes,